Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Aquestive therapeutics, inc. save search
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.75%
H: 0.57%
C: -3.45%
positive immunology meeting therapeutics
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
Published: 2023-07-27 (Crawled : 11:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 6.21%
H: 4.09%
C: -0.58%
positive topline therapeutics
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
Published: 2023-07-25 (Crawled : 12:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: -1.27%
H: 5.77%
C: 2.56%
conference positive topline therapeutics
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
Published: 2023-07-06 (Crawled : 12:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.2%
H: 3.57%
C: 1.19%
food positive global therapeutics
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 0.97%
H: 12.5%
C: 11.06%
positive therapeutics results study
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Published: 2023-02-21 (Crawled : 13:20) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.65%
H: 1.03%
C: -3.93%
aqst-109 immunology meeting therapeutics epinephrine positive
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
Published: 2022-11-09 (Crawled : 22:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.74%
H: 11.96%
C: 9.78%
aqst-109 immunology meeting therapeutics positive
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
Published: 2022-10-24 (Crawled : 12:20) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 3.0%
H: 0.33%
C: -3.98%
therapeutics positive
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
Published: 2022-10-11 (Crawled : 12:20) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.96%
H: 8.65%
C: 3.85%
aqst-109 fda therapeutics response epinephrine positive
Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®
Published: 2022-09-27 (Crawled : 12:00) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 12.05%
H: 1.2%
C: -9.16%
aqst-109 epipen trial therapeutics positive
Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film
Published: 2022-07-11 (Crawled : 12:20) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 0.37%
H: 19.74%
C: 7.89%
aqst-109 trial therapeutics epinephrine positive results
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Published: 2022-06-15 (Crawled : 21:00) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: -2.74%
H: 4.65%
C: -15.49%
aqst-109 topline trial therapeutics epinephrine positive
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Published: 2022-04-12 (Crawled : 12:20) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: -1.85%
H: 6.6%
C: 1.89%
aqst-109 topline therapeutics epinephrine positive
Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Published: 2022-03-01 (Crawled : 02:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 2.51%
H: 6.29%
C: 0.7%
aqst-109 america therapeutics epinephrine phase 1 positive results topline immunology
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Published: 2022-02-25 (Crawled : 12:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 7.66%
H: 0.0%
C: 0.0%
aqst-109 trial therapeutics epinephrine report positive topline
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
phase 1 positive topline trial phase 2 phase 3
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Published: 2021-10-25 (Crawled : 13:00) - aquestive.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
Published: 2021-10-25 (Crawled : 13:00) - globenewswire.com
AQST | $4.28 -2.28% -2.7% 24K
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.